4 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 5 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Gallbladder Adenocarcinoma: new trials by email Literature Review of Gallbladder Adenocarcinoma trials Research Report on Gallbladder Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test - Foregut Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Recruiting | Yale University | 54 | 2026-06-02 | 2026-09-08 |
| Evaluating Novel Therapies in ctDNA Positive GI Cancers Atezolizumab, Bevacizumab - Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 3 | Active not recruiting | Georgetown University | 11 | 2023-03-29 | 2026-10-06 |
| Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma HIPEC - Gallbladder Adenocarcinoma | Early Phase 1 | Recruiting | West Virginia University | 10 | 2022-06-23 | 2026-04-20 |
| Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Standard of Care Chemotherapy, Video-Assisted Thoracic Surgery (VATS), Lobectomy - Metastatic Cancer, Foregut Carcinoid Tumor | Phase 2 | Withdrawn | University of Chicago | 2022-05-19 | 2024-07-31 | |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma PEGPH20, CIS, GEM - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic | Phase 1 | Terminated | Halozyme Therapeutics | 85 | 2017-10-02 | 2020-02-07 |
| ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer ADH-1, Cisplatin, Gemcitabine Hydrochloride - Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma | Phase 1 | Completed | University of Nebraska | 17 | 2013-04-09 | 2023-12-28 |
| Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Erlotinib Hydrochloride, Sorafenib Tosylate - Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2010-04-01 | 2015-06-30 |
| Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Bevacizumab, Gemcitabine, Oxaliplatin - Biliary Tract Cancer, Gallbladder Adenocarcinoma | Phase 2 | Completed | Massachusetts General Hospital | 35 | 2006-05-01 | 2017-02-07 |
| Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Capecitabine, Oxaliplatin, Bevacizumab - Biliary Tract Cancer, Gallbladder Adenocarcinoma | Phase 2 | Completed | Massachusetts General Hospital | 8 | 2004-12-01 | 2018-04-25 |
Cholangiocarcinoma (3) · Biliary Tract Neoplasms (2) · Gallbladder Neoplasms (2) · Klatskin Tumor (2) · Adenocarcinoma Of Esophagus (1) · Bile Duct Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Gastrointestinal Neoplasms (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1)
Neoplasms (8) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Neoplasms by Site (6) · Adenocarcinoma (5) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Biliary Tract Diseases (4) · Biliary Tract Neoplasms (2) · Gallbladder Diseases (2) · Gastrointestinal Diseases (2) · Liver Diseases (2) · Bile Duct Diseases (1) · Cholangiocarcinoma (1)
Bevacizumab (3) · Gemcitabine (2) · Oxaliplatin (2) · atezolizumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Anterior Temporal Lobectomy (1) · Capecitabine (1) · Cisplatin (1) · Erlotinib Hydrochloride (1) · Hyperthermic Intraperitoneal Chemotherapy (1) · Mitomycin (1) · N-Ac-CHAVC-NH2 (1) · PEGPH20 (1) · Platinum (1) · Radiotherapy (1)
Massachusetts General Hospital (2) · Georgetown University (1) · Halozyme Therapeutics (1) · National Cancer Institute (NCI) (1) · University of Chicago (1) · University of Nebraska (1) · West Virginia University (1) · Yale University (1)
United States (8) · South Korea (1) · Thailand (1)
Kiran Turaga, MD (2) · Andrew X. Zhu, MD (1) · Andrew Zhu, MD (1) · Anthony El-Khoueiry (1) · Brian Boone, MD (1) · Jean L Grem, MD (1) · John L. Marshall, MD (1)
P30CA036727 (1), P50CA127297 (1), U10CA032102 (1)